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Background: BRCA1 and BRCA2 (BRCA1/2)-deficient tumors display impaired homologous recombination repair (HRR) and
enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). Their efficacy in
germline BRCA1/2 (gBRCA1/2)-mutated metastatic breast cancers has been recently confirmed in clinical trials. Numerous
mechanisms of PARPi resistance have been described, whose clinical relevance in gBRCA-mutated breast cancer is unknown.
This highlights the need to identify functional biomarkers to better predict PARPi sensitivity.
Patients and methods: We investigated the in vivo mechanisms of PARPi resistance in gBRCA1 patient-derived tumor
xenografts (PDXs) exhibiting differential response to PARPi. Analysis included exome sequencing and immunostaining of DNA
damage response proteins to functionally evaluate HRR. Findings were validated in a retrospective sample set from gBRCA1/
2-cancer patients treated with PARPi.
Results: RAD51 nuclear foci, a surrogate marker of HRR functionality, were the only common feature in PDX and patient
samples with primary or acquired PARPi resistance. Consistently, low RAD51 was associated with objective response to PARPi.
Evaluation of the RAD51 biomarker in untreated tumors was feasible due to endogenous DNA damage. In PARPi-resistant
gBRCA1 PDXs, genetic analysis found no in-frame secondary mutations, but BRCA1 hypomorphic proteins in 60% of the models,
TP53BP1-loss in 20% and RAD51-amplification in one sample, none mutually exclusive. Conversely, one of three PARPi-resistant
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gBRCA2 tumors displayed BRCA2 restoration by exome sequencing. In PDXs, PARPi resistance could be reverted upon
combination of a PARPi with an ataxia-telangiectasia mutated (ATM) inhibitor.
Conclusion: Detection of RAD51 foci in gBRCA tumors correlates with PARPi resistance regardless of the underlying
mechanism restoring HRR function. This is a promising biomarker to be used in the clinic to better select patients for PARPi
therapy. Our study also supports the clinical development of PARPi combinations such as those with ATM inhibitors.
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Introduction
BRCA1 and BRCA2 encode essential proteins for DNA homolo-
gous recombination repair (HRR) [1]. Loss of function of either
gene impairs this high-fidelity DNA repair pathway and results in
genetic instability and an increased risk of breast or ovarian cancer
in germline BRCA1/2 (gBRCA) mutation carriers [2, 3]. Defective
HRR increases sensitivity of gBRCA-mutated tumors to DNA
damaging agents including anthracyclines, platinum salts, or to
novel agents that block parallel DNA repair pathways, including
poly(ADP-ribose) polymerase inhibitors (PARPi) [4–6]. PARP
inhibition blocks the repair of DNA single-strand breaks and
results in stalling of replication fork progression by trapping PARP
on the DNA break [7]. Both contribute to the accumulation of
DNA double-strand breaks (DSBs) that HRR-deficient cells can-
not repair efficiently.
PARPi are well-tolerated agents and elicit anticancer efficacy
in metastatic gBRCA tumors. Their use has been approved
for advanced ovarian cancer [olaparib (Lynparza
VR
), rucaparib
(Rubraca
VR
) and niraparib (Zejula
VR
)] and for gBRCA breast cancer
(BC) [8–10]. Final results from other phase III clinical trials are
awaited, both in the early and advanced BC setting (NCT01905592,
NCT01945775, NCT02032823).
Primary resistance to PARPi in a subset of gBRCA patients lim-
its the potential of gBRCA status as the only biomarker of
response to that of an enrichment strategy [11]. In addition,
acquired resistance in monotherapy responders is a challenge.
Previous studies using in vitro models, transgenic mice and
human tumor samples have delineated two types of resistance
mechanisms to PARPi in gBRCA cells: (i) independent of HRR
(cellular extrusion of the PARPi, PARP1 loss, FANCD2 overex-
pression, SLFN11 inactivation or CHD4 loss) and (ii) dependent
on HRR recovery, either by BRCA-independent mechanisms
(loss of 53BP1, REV7/MAD2L2, PAXIP1/PTIP, Artemis) or by
BRCA-dependent mechanisms [12–22]. The latter include secon-
dary BRCA1/2 mutations that restore the reading frame and the
expression of partially functional hypomorphic BRCA1 proteins
(BRCA1-11q alternative splice isoform, the RING-less BRCA1
generated by downstream translation initiation, or HSP90-medi-
ated stabilization of BRCA1 C-terminal mutants). Most work in
gBRCA clinical samples has focused on ovarian cancer and has
established that HRR recovery through secondary BRCA1/2
mutations may act as a resistance mechanism to platinum salts
and PARPi. Conversely, little is known about in vivo PARPi
resistance mechanisms in gBRCA BC [22].
Patterns of DNA aberrations in the tumors (genomic scars)
resulting from HRR deficiency may aid in distinguishing HRR-
deficient from HRR-proficient tumors [23–25]. However,
genomic scars in gBRCA tumors may persist after restoration of
HRR function [26]. In order to improve patient selection for
PARPi monotherapy among gBRCAmutation carriers, especially
in the metastatic setting, there is a clear need for a functional bio-
marker of HRR status to be used in the clinic. Previous work by
others showed that induction of nuclear foci of the HRR protein
RAD51 after neoadjuvant chemotherapy is a measure of HRR
functionality in BC biopsies and predicts treatment response
[27]. Here, we sought to investigate RAD51 foci as an indicator of
functional HRR and its correlation with PARPi resistance in the
gBRCA setting. We further explored potential treatment strat-
egies for PARPi-resistant BC.
Methods
Study design
A collection of patient-derived tumor xenograft (PDX) models was gener-
ated by implanting tumor samples from patients with a germline BRCA1/2
mutation and breast or ovarian cancer. Their sensitivity to PARPi was eval-
uated, and the functionality of the HRR pathway was analyzed and com-
pared between the PARPi-sensitive versus the PARPi-resistant PDX
samples to find a functional test correlating with response. An exploratory
analysis in a set of 20 tumor samples including patients treated with PARPi
at our institution was employed to confirm the findings and the potential
clinical interest of the functional test. A new therapeutic PARPi combina-
tion was tested in vivo in PARPi-resistant PDXmodels.
See further methods in supplementary material, available at Annals of
Oncology online.
Results
gBRCA PDX panel
Fresh tumor samples prospectively collected for implantation into
nude mice yielded a total of 12 PDX models (11 gBRCA1 and 1
gBRCA2) (supplementary Table S1, available atAnnals of Oncology
online). Five models were derived from patients with metastatic
disease who had been treated with PARPi, three of which prior to
olaparib treatment and two at progression after a sustained partial
response (PR) (supplementary Table S1, available at Annals of
Oncology online). Persistence of the gBRCA mutations was con-
firmed in all models but PDX274, and they were associated with
loss of heterozygosity, i.e. loss of the wild type allele (supplemen-
tary Figure S1, available atAnnals of Oncology online).
Olaparib treatment in the gBRCA PDX collection distin-
guished a subset of PARPi-resistant tumors (Figure 1A) [assessed
by modified Response Evaluation In Solid Tumors (mRECIST),
see supplementary methods, available at Annals of Oncology
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Figure 1. Homologous recombination repair markers and PARPi response. (A) Antitumor activity of olaparib in gBRCA patient-derived tumor
xenografts (PDXs). Best response to olaparib is plotted as the percentage of tumor volume change after at least 21 days of treatment. þ20%,
–30% and –95% are marked by dashed lines to indicate the range of CR (complete response), PR (partial response), SD (stable disease) and
PD (progressive disease). Mut, mutation; B1, mutation in BRCA1; B2, mutation in BRCA2; Metastatic, PDX derived from a metastatic lesion (oth-
erwise, derived from a primary tumor); TNBC, triple negative BC; ERþ, estrogen receptor positive BC; OvCa, ovarian cancer. (B)
Immunoﬂuorescence staining of BRCA1, 53BP1 and RAD51 across the PARPi-sensitive and PARPi-resistant gBRCA PDX models. Detection of
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online]. Treatment with olaparib exhibited antitumor activity in
three gBRCA models: two complete responses (CR) and one sta-
ble disease (SD). The remaining nine PDXmodels were olaparib-
resistant (PD). An additional PDX model with acquired resist-
ance (PDX230OR) was generated from its PARPi-sensitive coun-
terpart (PDX230) after >100 days exposure to olaparib
(supplementary Figure S2, available at Annals of Oncology
online), totaling 13 gBRCA1/2 models. Among the four PDX
derived from gBRCA primary tumors, 50% showed CR. The sen-
sitivity to PARPi-treatment in the PDXs from metastatic patients
previously treated with olaparib mirrored the patients’ clinical
response to olaparib (supplementary Table S1 and Figure S3,
available at Annals of Oncology online).
BRCA1/2 sequencing, BRCA1 expression and
nuclear foci formation in gBRCA PDX samples
No frameshift-correction or genetic reversion of the inherited
mutation—the so-called secondary BRCA mutations—occurred
in the gBRCA1 PARPi-resistant PDXs. BRCA1mRNA expression
was variable across models and absent in PDX280, a model with a
large deletion encompassing the complete BRCA1 gene (supple-
mentary Figure S4, available at Annals of Oncology online). To
investigate the potential expression of hypomorphic BRCA1 iso-
forms and their recruitment to DNA damage sites, we set up
immunostaining assays for the DNA damage response (DDR)
proteins: BRCA1, RAD51 (as functional HRR marker) and
cH2AX (as DNA damage marker), with geminin (as S/G2-cell
cycle marker) (supplementary Figure S5, available at Annals of
Oncology online).
PDX124 and PDX196 harbor a c.1961delAmutation in BRCA1
exon 11 and express the BRCA1-D11q splice isoform
(p.Ser264_Gly1366del) [20] which forms nuclear foci detected
with both B1-NT and B1-CT antibodies, as expected (Figure 1B
and supplementary Figure S6, available at Annals of Oncology
online). BRCA1 nuclear foci were also detected in five additional
gBRCA PDX models: PDX179, STG316, PDX274, PDX221 and
PDX236 (supplementary Table S1, available at Annals of
Oncology online and Figure 1B). Western blot confirmed the
expression of BRCA1 isoforms at the respective predicted sizes
[D11q, RING-less, and C-terminal truncated mutant proteins
(supplementary Figure S7, available at Annals of Oncology
online)]. In summary, hypomorphic BRCA1 isoforms were
detected by immunofluorescence (IF) to form nuclear foci in
seven PDX models, six with primary or acquired resistance to
PARPi and onemodel showing disease stabilization (PDX124).
Analysis of 53BP1 loss and exome sequencing in
gBRCA PDX samples
The assessment of 53BP1 nuclear foci by IF in olaparib-treated
PDX samples identified 53BP1 loss in two PARPi-resistant mod-
els: PDX230OR and STG316 (Figure 1B). Exome sequencing
unveiled somatic mutations in TP53BP1 in both models (supple-
mentary Table S1, available at Annals of Oncology online). The
PD model PDX280 harbors a non-previoulsy reported missense
mutation in the PARPi resistance gene SLFN11 p.H661D. The SD
model PDX124 displays a focal RAD51 amplification and high
protein expression (supplementary Figure S8A and B, available at
Annals of Oncology online). Mutations in other known PARPi
resistance genes (PARP1, REV7/MAD2L2, PAXIP1/PTIP,
Artemis,CHD4) were not identified.
Nuclear foci formation of the HRR protein RAD51
The observed recruitment of hypomorphic BRCA1 isoforms to
DNA damage sites and/or 53BP1 loss in PARPi-resistant PDXs
may help restore their ability to accomplish HRR. As a functional
surrogate of HRR, we sought to detect RAD51 nuclear foci in
geminin-positive cells and nuclear co-localization with BRCA1.
RAD51 nuclear foci were detected in 11 PDXs in olaparib-treated
samples, including all models expressing hypomorphic BRCA1
isoforms and/or lacking 53BP1 (Figure 1B). RAD51 foci co-
localized with BRCA1 foci in all PDXmodels expressing hypomor-
phic BRCA1 isoforms (supplementary Figure S9, available at
Annals of Oncology online). The three PARPi-resistant models that
lacked hypomorphic BRCA1 isoform expression or 53BP1 loss
(PDX127, PDX252 and PDX280) exhibited RAD51 foci suggesting
that recovery of HRR occurs via BRCA1-independentmechanisms
in these models (Figure 1B). Olaparib-treated samples from
PARPi-resistant PDXs showed higher percentage of RAD51-
positive cells versus those from PARPi-sensitive models (366 2%
in PARPi-resistant versus 56 3% in PARPi-sensitive, P¼ 0.0017)
(Figure 1C). Analysis of cH2AX foci ruled out PARPi pharmaco-
dynamic differences as the reason for this differential response
BRCA1 [with an antibody towards the N-terminus of BRCA1 (B1-NT) or C-terminus (B1-CT)], 53BP1 and RAD51 nuclear foci in olaparib-treated
PDX models. CR, PD and SD are indicated. For BRCA1, the location of the mutation within the gene is indicated. DAPI staining is shown in
blue. Green nuclei indicate geminin-positive cells (S/G2 phase of the cell cycle). (C) RAD51 nuclear foci formation discriminates PARPi-resist-
ant tumors. Quantiﬁcation of geminin positive cells with RAD51 nuclear foci detected by immunoﬂuorescence in FFPE samples from tumors
treated with vehicle (black bars) or olaparib (green bars). The graph displays mean6 SEM from three independent tumors. The association
with PARPi-response is shown in the supplementary Table S1, available at Annals of Oncology online. Dark grey, CR; light gray, SD; white, PD.
For RAD51, dark gray means high RAD51 score; light gray, intermediate RAD51; white, low RAD51. Expression of hypomorphic BRCA1 iso-
forms and loss of 53BP1 is depicted in dark gray. (D) RAD51 in patients’ tumors is associated with PARPi clinical response. IF of RAD51 and
geminin in the pretreatment setting using a pretreatment tumor sample (or the most recent metastatic sample). Samples from three PARPi-
resistant patients (Pt179, skin metastasis of TNBC; Pt183, dermal lymphatic carcinomatosis of ovarian cancer; Pt034, lymph node metastasis of
ERþ BC) and four PARPi-sensitive patients (Pt310pre, liver metastasis of ERþ BC; Pt124pre, primary TNBC; Pt280, peritoneal implant of ovarian
cancer; Pt04, lymph node metastasis TNBC) are shown. For acquired resistance, samples obtained from three patients at PARPi progression
(Pt310post, liver metastasis; Pt124post, skin metastasis; Pt201, skin metastasis of ERþ BC) are shown. Empty arrowheads show geminin-posi-
tive cells devoid of RAD51 nuclear foci. Solid arrowheads indicate RAD51/geminin-positive cells. DAPI staining is shown in blue. (E)
Quantiﬁcation of RAD51/geminin-positive cells from tumor samples shown in panel D. Pt183 was not scored as the tumor did not contain
100 geminin-positive cells. Unpaired t test: *P< 0.05; **P< 0.01.
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(supplementary Figure S10, available at Annals of Oncology
online). The unexpected evidence of endogenous DNA damage
and repairmarkers in untreated samples (supplementary Figure S5
and S10, available at Annals of Oncology online) prompted us to
also score RAD51 foci in untreated tumors (Figure 1C).
Importantly, untreated samples of PARPi-resistant tumors showed
a significantly higher baseline percentage of RAD51-positive cells
compared with PARPi-sensitive tumors (246 2% versus 36 2%,
P¼ 0.0025). Thus, HRR functionality was frequent and associated
with PARPi resistance in this gBRCA PDXpanel.
RAD51/geminin score and response to PARPi in
patients’ samples
We confirmed the feasibility of detecting RAD51 and cH2AX foci
in FFPE tumor samples from patients, by firstly staining for
RAD51 and geminin in 20 patients’ tumor samples including some
matched with the gBRCA PDX models (n¼ 7) (supplementary
Figure S11A–C, available at Annals of Oncology online). These
results prompted us to further assess the potential clinical utility of
the RAD51/geminin score as a functional biomarker of PARPi
treatment in patients treated with various PARPi at our institution
(n¼ 10 tumors), including two paired pre-/post-PARPi samples.
This cohort included eight patients with germline mutations in
BRCA1/2 (BRCA1, n¼ 5; BRCA2, n¼ 3; diagnosis of BC, n¼ 6;
ovarian cancer, n¼ 2). The samples had been collected prior to
(n¼ 7) or at progression to treatment with a PARPi (n¼ 3). We
stained and scored for RAD51 (Figure 1D and E). Importantly,
PARPi-resistant tumor samples showed an inverse relationship
between the RAD51 score and clinical efficacy of the PARPi.
Exome sequencing identified a BRCA2-secondary mutation in one
tumor with acquired resistance and RAD51 foci (supplementary
Figure S12, available atAnnals of Oncology online).
Platinum salts in olaparib-resistant tumors
HRR recovery/retention that limits PARPi efficacy may not imply
resistance to platinum-based treatments in gBRCA cancers. A
previous study in gBRCA ovarian cancer showed a 40% response
rate to platinum chemotherapy in the setting of resistance to ola-
parib [28]. We next assessed the efficacy of cisplatin in the two
HRR proficient, RAD51-positive ovarian cancer PDX models
(PDX196 and PDX280) (Figure 2A). Response to cisplatin was
confirmed in both PDX models and in the clinic for Pt280 (data
not available for Pt196 due to carboplatin hypersensitivity). Next,
we assessed the activity of platinum-based chemotherapy in
advanced/metastatic BC in the context of PARPi resistance. We
previously reported that PDX127 showed resistance to PARPi but
response to platinum, in agreement with the clinical response of
the patient [29]. Similarly, the PARPi-resistant models, RAD51-
positive model PDX252 exhibited significant tumor regression
when treated with cisplatin (Figure 2A). In the PARPi-resistant
PDX236 and PDX274, cisplatin-only slowed tumor growth as
compared with vehicle, while its combination with olaparib
achieved PR and SD, respectively (Figure 2B). These results high-
light that platinum-based therapies can be active in PARPi-
resistant metastatic BC and suggests that RAD51 foci formation
does not predict resistance to platinums in this setting.
Ataxia-telangiectasia mutated blockade plus PARP
inhibition in olaparib-resistant tumors
We further explored the potential of DDR inhibitors to enhance
PARPi antitumor activity. The ataxia-telangiectasia mutated
(ATM) kinase is activated in response to DNA DSBs, signals to cell
cycle checkpoints and DNA repair pathways, and is reciprocally
synthetic lethal with PARP [30]. As previously suggested, we
hypothesized that ATM inhibition is a treatment option for
PARPi-resistant BRCA1-deficient tumors that restore HRR
through loss of TP53BP1 or REV7/MAD2L2 by enabling ATM-
dependent end resection [17, 18]. We tested this hypothesis in
three ATM-expressing PDXs (supplementary Figure S13A, avail-
able at Annals of Oncology online): STG316, a model that lacks
53BP1, and in PDX127 and PDX280, which are devoid of hypo-
morphic BRCA1 isoforms, and presumably achieve PARPi resist-
ance by a ‘loss of 53BP1’-like mechanism. In fact, PDX127 harbors
a missense mutation in PRCC p.P55T, within the interaction
domain with REV7/MAD2L2 (supplementary Figure S13B, avail-
able at Annals of Oncology online). The best antitumor activity of
the olaparib combination with the ATM inhibitor AZD0156 was
achieved in PDX127 (SD) (Figure 2C). We investigated whether
ATM inhibition resulted in restoration of HRR deficiency by
impairing RAD51 foci formation [17, 18] (supplementary Figure
S13C, available at Annals of Oncology online). Unexpectedly,
RAD51 foci formation was marginally reduced in combination-
treated tumors, arguing that ATM inhibition may exert a broader
effect in signaling the olaparib-induced DDR beyond its effects on
HRR (supplementary Figure S13C, available at Annals of Oncology
online). Quantification of DNA damage by cH2AX staining (pan-
nuclear, Figure 2D and foci formation, supplementary Figure
S13D, available at Annals of Oncology online) showed a significant
increase of pan-cH2AX-positive cells upon ATM plus PARPi as
compared with olaparib monotherapy in combination-responders
PDX127 and STG316. These results suggest an induction of repli-
cation stress in these combination-sensitive models. These results
are of interest since an international phase I clinical trial testing the
tolerability of olaparib in combination with AZD0156 in solid
tumors is currently ongoing (NCT 02588105).
Discussion
There is a need to refine the determinants of PARPi efficacy
beyond gBRCA mutations, especially in the metastatic setting.
Our analysis of RAD51 foci in a total of 20 BC patient samples, 10
gBRCA1 and 10 gBRCA2, provides new evidence in favor of
restoration of HRR functionality as a frequent mechanism of
PARPi resistance, and demonstrates the potential of functional
biomarkers to discriminate tumors that will fail PARPi mono-
therapy. The RAD51 foci assay may capture the dynamic changes
in DNA repair that occur throughout tumor evolution and may,
therefore, more effectively identify the HRR-deficient BRCA1/2-
mutated tumors. Unexpectedly, while previous studies reported
low levels of baseline DNA damage as a potential limitation to
evaluate HRR [27, 31], we were able to detect it and score for
RAD51 in untreated samples, which correlated with PARPi
response. This highlights that an IF assay for RAD51 staining is
feasible in FFPE samples and suggests that testing for RAD51may
Annals of Oncology Original article
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be directly transferrable to the clinical setting when a larger study
confirms our findings.
Restoration of HRR can be achieved by secondary BRCA muta-
tions and may be captured by sequencing techniques [32, 33]. We
identified a BRCA2 secondary mutation in one BC patient with
acquired resistance to olaparib, whereas we did not detect in-frame
secondary mutations in any gBRCA1 PDXmodel. Our data suggest
that hypomorphic BRCA1 isoforms contribute to HRR restoration
in gBRCA1 BC [20, 21]. Importantly, high RAD51 score predicted
poor response to PARPi monotherapy independently of the
underlying mechanism of HRR restoration. Further research is
needed to establish the RAD51 score cut-off that differentiates res-
ponders from nonresponders to PARPi monotherapy and to evalu-
ate the potential impact of RAD51-independent resistance
mechanisms that involve replication fork stabilization [14, 16, 34,
35]. A high RAD51 foci score may encourage the use of combina-
tion therapies with PARPi, such as those that inhibit HRR [29, 36],
or that enhance DNA damage [9, 37, 38]. Here, we propose that a
subset of PARPi-resistant gBRCA tumors benefit from combined
PARPplus ATMblockade [17, 30, 39].
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Figure 2. Cisplatin or ATM inhibition overcomes PARPi resistance. (A) Relative tumor volume (RTV) of vehicle, cisplatin or olaparib in PDX196,
PDX280 and PDX252. Cisplatin was administrated 6mg/kg weekly unless RTV< 0.5. Olaparib was administrated daily at 50mg/kg (5 doses/
week). Number of tumors per arm is indicated. (B) RTV of vehicle, cisplatin, olaparib or its thereof combination in PDX236 and PDX274.
Cisplatin and olaparib were administrated as in panel A. (C) RTV of vehicle, olaparib, AZD0156 or the combination of treatments in PDX127,
STG316 and PDX280. Olaparib was administrated daily at 50mg/kg (5 doses/week) and AZD0156 was administered three times per week at
2 or 2.5mg/kg. (D) Quantiﬁcation of pan-nuclear cH2AX-positive cells in PDX127, STG316 and PDX280 treated with vehicle, olaparib,
AZD0156 or the combination of drugs at the end point of experiments shown in panel C. All ﬁgures show mean and SEM. Statistical P-values
are shown when relevant: *P< 0.05; **P< 0.01; ***P< 0.001; ****P< 0.0001 (two-way ANOVA).
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Our study unveils coexistence of various mechanisms of
PARPi resistance in each individual tumor, such as hypomorphic
BRCA1 isoforms together with RAD51 amplification or 53BP1
[40] loss. In conclusion, this emphasizes the need of comprehen-
sive functional tests for measuring HRR activity such as the
RAD51 assay to better select patients who will benefit most from
PARPi monotherapy and those who may benefit from a combi-
nation therapy.
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